A Mayo Clinic research team has found evidence suggesting that premenopausal women who are not at high risk of ovarian cancer should not have their ovaries removed for the purpose of cancer prevention. Premature removal of the ovaries can lead to a higher risk of anywhere from 8 to 18 chronic health conditions including coronary … Continued
(October 11, 2016) According to research published this month in the New England Journal of Medicine, the PARP inhibitor niraparib improves progression free survival in recurrent, platinum-sensitive women both with and without germline BRCA mutations. In a randomized, double-blind, phase III trial of over 550 women both with and without germline BRCA mutations, researchers found … Continued
Our #30DaysofTeal campaign spotlighted education and awareness facts about ovarian cancer. You, this amazing and strong community helped us educate 2.5 MILLION people about ovarian cancer throughout September. But awareness doesn’t stop today. Follow us year-round for the latest updates on research, advocacy and news about ovarian cancer. Today’s #30DaysofTeal sponsored by AstraZeneca US Community … Continued
Over 30,000 women and caregivers have found friends, support, strength and community on OCRFA’s Ovarian Cancer Community on Inspire. If you haven’t signed up yet, visit today to meet your online community. This #30DaysofTeal proudly sponsored by Astrazeneca
Have you seen our State Report Card, “50 States of Teal”? “50 States of Teal” revealed an overall trend: where a woman lives has a significant impact on her healthcare. Visit www.50statesofteal.org to read the report and see how your state scored. Plus find ways to take action at home. A woman’s healthcare shouldn’t be … Continued
Family history also contributes to a woman’s risk of ovarian cancer. Women who have one first-degree relative with ovarian cancer but no known genetic mutation still have an increased risk of developing ovarian cancer. Family history of any of the following cancers may indicate an increased risk: Breast cancer, Ovarian cancer, Colon cancer, Pancreatic cancer … Continued
Meet a Researcher: We had the chance to interview Hui Shen, PhD, a 2016 Liz Tilberis Early Career Award grantee to get to know her! Read our interview here. OCRFA: Tell us about yourself. Dr. Hui Shen: My name is Hui Shen. I am originally from China, and had lived in Hong Kong and Los … Continued
Meet a Researcher: We had the chance to interview Dr. Hui Shen, a 2016 Liz Tilberis Early Career Award grantee to get to know her! Read our interview here. OCRFA: Tell us about yourself. Dr. Hui Shen: My name is Hui Shen. I am originally from China, and had lived in Hong Kong and Los … Continued
OCRFA and Dr. Elizabeth Swisher spoke about the exciting progress being made by the Stand Up to Cancer Ovarian Cancer Dream Team! The SU2C Ovarian Cancer Dream Team, funded by OCRFA and NOCC, got to work on year ago. Dr. Swisher, a gynecologic oncologist at the University of Washington and co-leader of the Dream Team, … Continued
The National Comprehensive Cancer Network Guidelines for Ovarian Cancer can help walk you through all aspects of an ovarian cancer diagnosis. It answers questions from before a diagnosis through the whole cancer care continuum. You can use this guide as a way to learn more and go back to your doctor with questions you might … Continued
Join us in asking Congress to pass oral chemotherapy parity legislation today. This legislation will ensure that patients have access to the best chemotherapy drugs available, including many personalized therapies. Send an Action Alert to your Members of Congress Today! Why do we need this action now? The last decade has seen an explosion in … Continued
Miss USA, Deshauna Barber, joined Chad Ramsey and Lisa Mauti on Capitol Hill to meet with Members of Congress to educate them about ovarian cancer. Deshauna spoke with Members about Oral Chemotherapy Parity, asked for more research and awareness, and let them know just how important our community is.
Get email updates about research news, action alerts, and ways to join the fight.
